Efficacy of neoadjuvant TCHP regimen with empegfilgrastim in early HER2-positive breast cancer: Final analysis of the DEFENDOR SPECIAL study, HER2+ BC cohort
Authors:
- Liudmila G. ZhukovaLZLiudmila G. Zhukova
- Tansylu M. IbragimovaTITansylu M. Ibragimova
- Daria A. FilonenkoDFDaria A. Filonenko
- Inna P. GanshinaIGInna P. Ganshina
- Irina V. SorokinaISIrina V. Sorokina
- Andrei A. LazarevALAndrei A. Lazarev
- Olga N. MironenkoOMOlga N. Mironenko
- Oxana N. ProsianikovaOPOxana N. Prosianikova
Open Access
- 8 April 2026
- journal article
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 21-29
Abstract
Background. The DEFENDOR SPECIAL study (NCT04905329) evaluated the efficacy and safety of combination chemotherapy with empegfilgrastim for the primary prevention of neutropenia in patients with malignancies at high risk of recurrence. This article presents the results of an investigator-initiated analysis assessing the efficacy and safety of empegfilgrastim (Extimia®) in patients with stage II–III HER2-positive breast cancer (HER2+ BC) who received neoadjuvant therapy (NAT) with the TCHP regimen. Aim. To assess the clinical efficacy and safety of prolonged granulocyte colony-stimulating factor empegfilgrastim in patients with early HER2+ BCG treated with NAT as part of the TCHP regimen. Materials and methods. Data from 105 patients were analyzed. For the primary prevention of febrile neutropenia (FN), all patients received subcutaneous empegfilgrastim at a dose of 7.5 mg once per course. The primary endpoint was the relative dose intensity of the NAT courses, and the secondary endpoints included the complete pathomorphologic regression (pCR) rate, residual cancer burden (RCB), and adverse event rate. Comparison of pCR rates in this study and in the external control group of patients with early HER2+ BC of the clinical stage cT2-cT4/cN0-cN3/cM0, who received NAT in the TCHP regimen with filgrastim for the FN prevention from April 2020 to September 2023 at the Loginov Moscow Clinical Scientific Center. The matching based on the initial characteristics was performed using complete matching with the Mahalanobis distance. Results. In the DEFENDOR SPECIAL study, the median age (Q1–Q3) was 53 (43–61) years. The median relative dose intensity (Q1–Q3) was 97.1% (76.8–104.9%). PCR was achieved in 72.5% (76/105) of patients, while RCB-I and RCB-II were observed in 6.6% (7/105) and 15.2% (16/105), respectively. The highest pCR rate was observed in patients with HR-negative/HER2-positive (3+) tumors at 85.3% (29/34). No FN events were reported. Grade III–IV neutropenia occurred in 2.9% (3/105) of patients, grade I–II thrombocytopenia in 34.3% (36/105), and grade III thrombocytopenia in 1.0% (1/105). The probability of achieving pCR with empegfilgrastim was statistically significantly higher compared to filgrastim, with an adjusted odds ratio of 1.73 (95% confidence interval 1.04–2.89; p = 0.0357). Conclusion. Primary prevention of FN with empegfilgrastim offers a significant advantage in achieving pCR compared to filgrastim in patients with early HER2-positive breast cancer receiving a neoadjuvant TCHP regimen.Keywords
This publication has 46 references indexed in Scilit:
- Tumor infiltrating lymphocytes in breast cancer: A narrative review with focus on analytic validity, clinical validity, and clinical utilityHuman Pathology, 2025
- 133P Impact of tumor-infiltrating lymphocytes (TILs) on the pathological complete response (pCR) after neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancerESMO Open, 2025
- 1865P DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancersAnnals of Oncology, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulationCytokine, 2021
- Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancerCancer, 2020
- Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in AsiaJAMA Oncology, 2020
- Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung CancerCancer Cell, 2016
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term OutcomesJAMA Oncology, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014